BioSpace News Archive

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2023 financial results and provided a corporate update.

NANOBIOTIX announces the closing of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares in the form of American Depositary Shares.

Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date.

DaVita Inc. announced financial and operating results for the quarter ended September 30, 2023.

Veracyte, Inc. (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument.

Arcus Biosciences, Inc. (NYSE:RCUS) today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.

The Menarini Group and SciClone Pharmaceuticals Ltd. announced that they have entered into an exclusive sub-licensing agreement to develop and commercialize ORSERDU® in the People’s Republic of China, in an effort to expand treatment options for appropriate metastatic breast cancer patients.

Scopus BioPharma Inc. and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.